Europe's Flavors of Sustainable BioPharma
Executive Summary
Europe's financing environment makes it difficult to build big biotech from scratch. But sustainable biopharma firms are nevertheless emerging--mostly through the transformation of existing pharma assets.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008
Highlights from the Q1 2008 review of pharmaceutical and biotechnology dealmaking: there was a drought in biopharma financings--particularly from the public markets with only two completed IPOs--but VC funding was strong and made up 40% of the total. M&A activity was also down and saw only one multi-billion dollar deal. In alliances, oligonucleotides were the subject of seven biopharmaceutical collaborations and accounted for most of the quarter's dealmaking money.
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q1 2008
Highlights from the Q1 2008 review of pharmaceutical and biotechnology dealmaking: there was a drought in biopharma financings--particularly from the public markets with only two completed IPOs--but VC funding was strong and made up 40% of the total. M&A activity was also down and saw only one multi-billion dollar deal. In alliances, oligonucleotides were the subject of seven biopharmaceutical collaborations and accounted for most of the quarter's dealmaking money.
Organon Reboots with Biotech
Organon's biologics R&D push relects similar moves by other mid-sized firms, and could help the company recover after a series of setbacks. But building biotech from discovery upwards will take time.